__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Read more about PIQRAY^® (alpelisib), always given in combination with fulvestrant.

PIQRAY^® (alpelisib) is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy.

 

PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.

Reference

1. PIQRAY^® (alpelisib) Summary of Product Characteristics. Novartis Pharma; 2020.